Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.34
-1.70 (-0.69%)
AAPL  315.32
-0.90 (-0.28%)
AMD  557.89
+11.17 (2.04%)
BAC  59.67
+0.42 (0.71%)
GOOG  355.03
-1.21 (-0.34%)
META  669.21
+37.73 (5.97%)
MSFT  385.10
+0.74 (0.19%)
NVDA  210.96
+8.18 (4.03%)
ORCL  140.64
-3.08 (-2.14%)
TSLA  407.76
+1.21 (0.30%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.